title: 15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway.
abstract: Peroxisome proliferator-activated receptor gamma (PPARgamma) inhibits cell growth via promoting apoptosis. Human colorectal cancer tissues had abundant PPARgamma but the incidence of apoptosis was very low, suggesting a defect in the PPARgamma pathway. Here, we found that 15-hydroxy-eicosatetraenoic acid (15S-HETE), an endogenous ligand for PPARgamma, was significantly decreased in the serum of patients with colorectal cancer. Treatment of colon cancer cells with 15S-HETE inhibited cell proliferation and induced apoptosis, which was preceded by an increase in TGF-beta-inducible early gene (TIEG) and a decrease in Bcl-2. The action of 15S-HETE could be blocked when PPARgamma was suppressed. Overexpression of Bcl-2 prevented the apoptosis. The levels of TIEG and 15-lipoxygenase (15-LOX), the enzyme responsible for 15S-HETE production, was decreased in colorectal cancer. Therefore, colorectal cancer is associated with decreased 15S-HETE. Treatment of colon cancer cells with 15S-HETE inhibits cell proliferation and induces apoptosis in a PPARgamma-dependent pathway involving augmentation of TIEG and reduction of Bcl-2 expression.
authors.affiliation: Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong. gchen@cuhk.edu.hk
authors.forename: George G
authors.initials: GG
authors.lastname: Chen
authors.forename: Hu
authors.initials: H
authors.lastname: Xu
authors.forename: Janet F Y
authors.initials: JF
authors.lastname: Lee
authors.forename: Malayannan
authors.initials: M
authors.lastname: Subramaniam
authors.forename: Ka L
authors.initials: KL
authors.lastname: Leung
authors.forename: Su H
authors.initials: SH
authors.lastname: Wang
authors.forename: Ursula P F
authors.initials: UP
authors.lastname: Chan
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Spelsberg
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology; D004268:DNA-Binding Proteins / Q000378:metabolism; D051765:Early Growth Response Transcription Factors; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000494:pharmacology*; D007150:Immunohistochemistry; D051741:Kruppel-Like Transcription Factors; D008084:Lipoxygenase / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D011994:Recombinant Proteins / Q000187:drug effects; D012004:Rectal Neoplasms / Q000473:pathology; D014157:Transcription Factors / Q000187:drug effects / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D004268:DNA-Binding Proteins; D051765:Early Growth Response Transcription Factors; D006893:Hydroxyeicosatetraenoic Acids; C098111:KLF10 protein, human; D051741:Kruppel-Like Transcription Factors; D018160:Receptors, Cytoplasmic and Nuclear; D011994:Recombinant Proteins; D014157:Transcription Factors; C025984:15-hydroxy-5,8,11,13-eicosatetraenoic acid; D008084:Lipoxygenase